Open access · CC-BY
via OpenAlex
RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial
Translational Medicine of Aging · 2020 · ▲ 10 citations
Abstract
The biopharmaceutical company resTORbio, Inc. Recently announced termination of a phase 3 clinical trial evaluating the ability of the drug RTB101 to improve immune function in the elderly. The company reported that the first stage of the PROTECTOR1 trial did not meet its primary endpoint for reducing clinically symptomatic respiratory illness in healthy older adults. Although RTB101 has been described as an inhibitor of the mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR), the PROTECTOR1 trial was not a test of the geroscience hypothesis. Unlike the geroprotective compound rapamycin, RTB101 has not been found to increase lifespan or delay age-related functional or molecular phenotypes in pre-clinical animal models. RTB101 was first developed as an inhibitor of phosphoinositide-3-kinase (PI3K) with secondary inhibitory effects on mTOR. It’s ATP-competitive mechanism of action is distinct from the allosteric inhibition by rapamycin and does not specifically target mTOR complex 1 over mTOR complex 2. Clinical development of rapamycin and other specific mTOR complex 1 inhibitors to target age-related indications continues to be robust, and there is growing momentum for translational geroscience, with numerous clinical trials planned or ongoing in this area.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.tma.2020.01.002
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Kaeberlein, M.R. (2020). RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial. <em>Translational Medicine of Aging</em>. https://doi.org/10.1016/j.tma.2020.01.002
Vancouver
Kaeberlein MR. RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial. Translational Medicine of Aging. 2020. doi:10.1016/j.tma.2020.01.002.
BibTeX
@article{matt2020RTBand,
title = {RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial},
author = {Matt R. Kaeberlein},
journal = {Translational Medicine of Aging},
year = {2020},
doi = {10.1016/j.tma.2020.01.002},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Innovation in Aging 2019
Open access · CC-BY
A SYSTEM TO IDENTIFY INHIBITORS OF MTOR SIGNALING USING HIGH-RESOLUTION GROWTH ANALYSIS IN S. CEREVISIAE
Journal of Clinical Investigation 2013
Preprint · OA
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Springer eBooks 2018
Citation only
Inhibition of mTOR Signalling: A Potential Anti-aging Drug Strategy
British Journal of Clinical Pharmacology 2016
Open access · CC-BY
Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria‐related disorders
Journal of Neuroscience 2009
Open access · OA
Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability
2020
Preprint · OA